Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome
Archives of Medical Science, 05/10/2012
Olszanecka–Glinianowicz M et al. – The authors conclude that the visfatin/insulin ratio declining with increasing visceral obesity may predispose to the development of insulin resistance.
The study involved 92 obese women.
Subjects were diagnosed with MetS according to IDF 2005 criteria.
The MetS group consisted of 71 subjects (age: 52.8 ±9.4 years, body mass index [BMI]: 39.1 ±5.6 kg/m2, waist circumference: 109.6 ±11.4 cm and fat mass: 52.0 ±12.8 kg) while the non–MetS group consisted of 21 subjects (age: 51.7 ±9.5 years, BMI: 36.3 ±5.2 kg/m2, waist circumference: 104.7 ±11.0 cm and fat mass: 45.2 ±10.7 kg).
In addition to anthropometric measurements and assessment of serum glucose and lipids, plasma concentrations of visfatin were estimated by enzyme–linked immunosorbent assay (ELISA) and of insulin by radioimmunoassay (RIA).
Homeostatic model assessment insulin resistance (HOMA–IR) and visfatin/insulin ratio were calculated.
In the MetS group significantly higher (p < 0.01) plasma concentrations of insulin and HOMA–IR values but similar visfatin levels were observed than in the non–MetS group.
As a consequence of the significantly higher plasma insulin concentration the visfatin/insulin ratio was significantly lower in the MetS group (p < 0.05).
The visfatin/insulin ratio correlated inversely with anthropometric parameters such as body mass, BMI, body fat and waist circumference (r = –0.41, p = 0.0003; r = –0.42, p = 0.0002; r = –0.29, p = 0.01; r = –0.23, p = 0.04, respectively).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.